Published:
|
|
Is there any treatment?
Treatments for both NF1 and NF2 are presently aimed at controlling symptoms. Surgery can help some NF1 bone malformations
and remove painful or disfiguring tumors; however, there is a chance that the tumors may grow back and in greater numbers.
In the rare instances when tumors become malignant (3 to 5 percent of all cases), treatment may include surgery, radiation,
or chemotherapy. For NF2, improved diagnostic technologies, such as MRI, can reveal tumors as small as a few millimeters in
diameter, thus allowing early treatment. Surgery to remove tumors completely is one option but may result in hearing loss.
Other options include partial removal of tumors, radiation, and if the tumors are not progressing rapidly, the conservative
approach of watchful waiting. Genetic testing is available for families with documented cases of NF1 and NF2. New (spontaneous)
mutations cannot be confirmed genetically. Prenatal diagnosis of familial NF1 or NF2 is also possible utilizing amniocentesis
or chorionic villus sampling procedures.
What is the prognosis?
In most cases, symptoms of NF1 are mild, and patients live normal and productive lives. In some cases, however, NF1 can be
severely debilitating. In some cases of NF2, the damage to nearby vital structures, such as other cranial nerves and the brainstem,
can be life-threatening.
What research is being done?
Several years ago, research teams located the exact position of the NF1 gene on chromosome 17. The product of the NF1 gene
is a large and complex protein called neurofibromin. One portion of this protein is similar to a family of proteins called
GAP (guanosine triphosphatase-activating protein). Scientists have demonstrated that GAP proteins play a significant role
in tumor suppression in certain cancers. The similarity of the NF1 protein to GAP proteins suggests that the NF1 protein may
have a similar switching role in the development of neurofibromas. Scientists theorize that defects in the gene may lessen
or inhibit the normal output of its protein and allow the irregular cell growth that may lead to tumor development. Intensive
efforts have led to the identification of the NF2 gene on chromosome 22. The NF2 gene product is a tumor suppressor protein.
Basic studies in molecular genetics may lead one day to nonsurgical or pharmacologic treatments aimed at retarding or suppressing
tumors associated with the neurofibromatoses. The Interinstitute Medical Genetics Research Program at the NIH Clinical Center
conducts NF2 family history research. Using specimens from some of the families, scientists have isolated and sequenced the
NF2 gene and have described two different patterns of clinical features in NF2 patients. Investigators are continuing to study
these patterns to see if they correspond to specific types of gene mutations.
Synonyms: Von Recklinghausen's Disease